Actively Recruiting

Phase 3
Age: 6Months +
All Genders
NCT07265232

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Led by Lantu Biopharma · Updated on 2025-12-04

15

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study objective is to determine the real-world safety and effectiveness of Vesemnogene lantuparvovec for the treatment of SMA. The specific objectives are: * To determine clinical effectiveness of Vesemnogene lantuparvovec therapy for SMA as evaluated by developmental gross motor milestone and survival. * To describe the safety profile of Vesemnogene therapy for SMA as evaluated by adverse events reporting and laboratory tests, and monitoring of Adverse events of special interest.

CONDITIONS

Official Title

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Who Can Participate

Age: 6Months +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to give written informed consent for participation in the study.
  • Genetic confirmation of SMA (biallelic deletion or mutation of SMN1).
  • SMA clinical phenotype and condition, that in the opinion of the treating physician, treatment with Vesemnogene will likely be beneficial.
  • Absence of contraindications for spinal tap procedure or administration of intrathecal therapy.
  • Total AAV antibody titres less than 1:20 as determined by ELISA assay.
  • Normal liver function (AST/ALT less than 3 times upper limit of normal, Bilirubin less than 3.0 mg/dL).
  • Unable to access or failure to respond to currently available curative treatments for SMA.
Not Eligible

You will not qualify if you...

null

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tzu chi hospital

Jakarta, Indonesia, Indonesia, 14470

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here